Phase II Trial of Combination Immunotherapy with Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High Risk HER2+ Breast Cancer Patients

ID Number 15-1088

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


The goal of this clinical research study is to compare if and for how long trastuzumab combined with either NeuVax (nelipepimut-S given with GM-CSF [sargramostim]) or sargramostim can help to control the disease in patients with HER2 positive breast cancer.

Contact Information
Joni Gomes
(212) 824-7309

Recruiting Patients: Yes